Myriam Aburto

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Impact of changes in physical activity on health-related quality of life among patients with COPD

Cristóbal Esteban, José M. Quintana, Myriam Aburto et al. · European Respiratory Journal · 2010 · 188 citations

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Influence of changes in physical activity on frequency of hospitalization in chronic obstructive pulmonary disease

Cristóbal Esteban, Inmaculada Aróstegui, Myriam Aburto et al. · Respirology · 2014 · 81 citations

Impact of hospitalisations for exacerbations of COPD on health-related quality of life

Cristóbal Esteban, José M. Quintana, Javier Moraza et al. · Respiratory Medicine · 2009 · 78 citations

Pulmonary Care, Health-related Quality, Pulmonary Medicine +4